Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

#4513

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Aim(s): This study aims to investigate the potential efficacy of immunotherapy and compare the concordance of different PD-L1 antibody clones in NETs.

Materials and methods: We retrospectively reviewed the ZS001 clinical trial and identified two cases of NETs with high PD-L1 expression (TPS＞50%). IHC staining was performed on tissue sections using four PD-L1 antibody clones: SP142, 28-8, C0148, and E1L3N.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,